ARC 520

Drug Profile

ARC 520

Alternative Names: ARC-520

Latest Information Update: 18 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arrowhead Research Corporation
  • Developer Arrowhead Pharmaceuticals
  • Class Antivirals; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 11 Apr 2018 Updated efficacy data from the phase II Heparc-2001 trial in Hepatitis B presented at the International Liver Congress (ILC-2018)
  • 02 Dec 2016 Arrowhead Pharmaceuticals terminates a phase II trial in Hepatitis B in China, Germany and South Korea (NCT02604199)
  • 02 Dec 2016 Arrowhead Pharmaceuticals terminates a phase II trial in Hepatitis B in Hong Kong (NCT02065336)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top